Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Sparsentan by Travere Therapeutics for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
Sparsentan is under clinical development by Travere Therapeutics and currently in Phase III for Focal Segmental Glomerulosclerosis (FSGS). According to...